AstraZeneca Reports Imfinzi (durvalumab) & tremelimumab Results in P-III EAGLE trial for Advanced Head and Neck Cancer

 AstraZeneca Reports Imfinzi (durvalumab) & tremelimumab Results in P-III EAGLE trial for Advanced Head and Neck Cancer

AstraZeneca Reports Imfinzi (durvalumab) & tremelimumab Results in P-III EAGLE trial for Advanced Head and Neck Cancer

Shots:

  • The P-III EAGLE study involved assessing of Imfinzi as monothx or Imfinzi + tremelimumab vs SoC CT in patients with recurrent or metastatic HNSCC who experienced progression following Pt-based CT, at 169 centers across 24 countries
  • The P-III EAGLE study results demonstrated that it didn’t met 1EPs as OS and has shown safety and well-tolerated signs in patients 
  • Imfinzi (durvalumab) is a mAb, binds with PD-L1 and blocks its interaction with PD-1 and CD80, is approved in 40 countries including the US, EU and Japan for Stage III NSCLC. Tremelimumab is a mAb, used for targeting the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

Click here to read full press release/ article | Ref: AstraZeneca | Image Source: DW

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post